Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $478.39 +1.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $478.39 +1.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPGP
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $272.31, moving +0.79% from the previous trading session.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
The Zacks Analyst Blog Highlights Apple, NVIDIA, McDonald's, Cisco Systems and Vertex Pharmaceuticals
by Zacks Equity Research
Apple, NVIDIA, McDonald's, Cisco Systems and Vertex Pharmaceuticals have been included in this Analyst Blog.
Top Stock Reports for Apple, NVIDIA & McDonald's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA), and McDonald's Corporation (MCD).
5 Stocks in S&P 500 ETF That Gained Last Week
by Sweta Killa
The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY¿¿¿s portfolio have risen.
Strength Seen in Vertex (VRTX): Can Its 4.8% Jump Turn into More Strength?
by Zacks Equity Research
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $250.96, moving -1.01% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.86%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $254.88 in the latest trading session, marking a -1.86% move from the prior day.
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
by Zacks Equity Research
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
The Zacks Analyst Blog Highlights Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals
by Zacks Equity Research
Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Top Stock Reports for Alibaba, McDonald's & Advanced Micro Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), McDonald's Corporation (MCD), and Advanced Micro Devices, Inc. (AMD).
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical
by Zacks Equity Research
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
by Ekta Bagri
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results
by Zacks Equity Research
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.
Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline
by Zacks Equity Research
Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.